Barbara Tilley to Cost-Benefit Analysis
This is a "connection" page, showing publications Barbara Tilley has written about Cost-Benefit Analysis.
Connection Strength
0.126
-
Economic analysis of secondary trial data. Prog Cardiovasc Dis. 2012 Jan-Feb; 54(4):351-6.
Score: 0.082
-
Cost-effectiveness evaluation of the PROPPR trial transfusion protocols. Transfusion. 2020 05; 60(5):922-931.
Score: 0.036
-
Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA Stroke Study Group. Neurology. 1998 Apr; 50(4):883-90.
Score: 0.008